Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–56 of 56 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
NK Cell Infusion, Immunotherapy, Miltenyi Biotec CliniMACS device, Interleukin-2 (IL-2), Clofarabine, Cyclophosphamide, Etoposide
Other · Biological · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Mesothelioma
Interventions
Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Peritoneal Malignant Mesothelioma
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Pemetrexed Disodium, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Chicago, Illinois • Danville, Illinois + 31 more
Conditions
Malignant Pleural Mesothelioma
Interventions
Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
Biological
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • Chicago, Illinois + 2 more
Conditions
Prostate Cancer
Interventions
Ipilimumab, GM-CSF
Drug
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Borderline Resectable Pancreatic Adenocarcinoma
Interventions
Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
Biological · Radiation · Procedure
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Fort Myers, Florida • Columbus, Ohio
Conditions
Prostate Cancer
Interventions
Ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
42
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 36 more